We have collected information about Biodelivery Sciences Endo for you. Follow the links to find out details on Biodelivery Sciences Endo.
BioDelivery Sciences (BDSI) is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive ...
http://ir.bdsi.com/news-releases/news-release-details/biodelivery-sciences-reacquires-license-belbucatm-endo
BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) is marketed in the U.S. by BioDelivery Sciences. BELBUCA® (buprenorphine) buccal film (CIII) is commercialized in the U.S. by Endo Pharmaceuticals through January 8, 2017, pursuant to the worldwide licensing and development agreement between BDSI and Endo.
https://www.prnewswire.com/news-releases/endo-pharmaceuticals-and-biodelivery-sciences-announce-acceptance-of-nda-for-belbuca-buprenorphine-hcl-buccal-film-for-the-management-of-chronic-pain-300039475.html
Endo Pharmaceuticals and BioDelivery Sciences Announce Acceptance of NDA for BELBUCA™ (buprenorphine HCl) Buccal Film for the Management of Chronic Pain
http://ir.bdsi.com/news-releases/news-release-details/endo-pharmaceuticals-and-biodelivery-sciences-announce-nda
Learn more at www.endo.com. About BioDelivery Sciences International - BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery ...
https://www.prnewswire.com/news-releases/biodelivery-sciences-reacquires-license-to-belbuca-from-endo-pharmaceuticals-300375132.html
BioDelivery Sciences Reacquires License to BELBUCA™ from Endo Pharmaceuticals BELBUCA expected to be accretive to BDSI's 2017 net income and EPS
https://www.marketwatch.com/investing/stock/bdsi
BDSI Complete BioDelivery Sciences International Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
https://www.fiercebiotech.com/special-report/biodelivery-sciences-and-endo-pharmaceuticals
BioDelivery says that an unusually high placebo response was responsible for the failure. Now their R&D team can put the drug to the test one more time. BioDelivery Sciences and Endo Pharmaceuticals
https://www.prweb.com/releases/2012/1/prweb9086568.htm
BEMA Buprenorphine utilizes BioDelivery Sciences’ patented BioErodible MucoAdhesive (BEMA) technology to deliver the pain-reliving opiate drug. Per the agreement, Endo will be responsible for the manufacturing, distribution, marketing and sales of BEMA Buprenorphine on a worldwide scale.
https://www.marketwatch.com/press-release/biodelivery-sciences-closes-transaction-to-reacquire-license-to-belbuca-from-endo-pharmaceuticals-2017-01-09
Jan 09, 2017 · The BioDelivery Sciences and BUNAVAIL logos are trademarks owned by BioDelivery Sciences International, Inc. BELBUCA® is a trademark currently owned by Endo Pharmaceuticals.
https://investor.endo.com/news-releases/news-release-details/endo-pharmaceuticals-and-biodelivery-sciences-present-new-data
Sep 09, 2015 · Endo Pharmaceuticals is an operating company of Endo International plc, a global specialty pharmaceutical company focused on improving patients' lives while creating shareholder value. Learn more at www.endo.com or www.endopharma.com. About BioDelivery Sciences International
Searching for Biodelivery Sciences Endo?
You can just click the links above. The data is collected for you.
